Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HBI-2376 + HBI-2438 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HBI-2376 | HBI 2376|HBI2376 | SHP2 Inhibitor 20 | HBI-2376 inhibits SHP2, potentially leading to decreased tumor cell proliferation and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 1041). | |
| HBI-2438 | HBI2438|HBI 2438 | KRAS G12C inhibitor 36 | HBI-2438 selectively inhibits KRAS G12C, leading to decreased downstream signaling and potentially resulting in decreased tumor cell proliferation and inhibition of tumor growth (NCI Drug DIctionary, Mol Cancer Ther (2023) 22 (12_Supplement): A097). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|